J&J Can't Escape Retailers' Antitrust Suit Over Remicade
Johnson & Johnson must face an antitrust suit accusing the drugmaker of foisting the brand drug Remicade on pharmacies and preventing them from carrying competing biosimilars, according to a Pennsylvania federal...To view the full article, register now.
Already a subscriber? Click here to view full article